Type 1 Diabetes Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with Type 1 diabetes and are at least 2 years old
- People who have been prescribed a specific insulin pump system called the Omnipod 5, used together with a FreeStyle Libre 2 Plus sensor, within the last year
- People who have never used the Omnipod 5 System before joining the trial
- People who have agreed to allow their personal data to be used for this study
- People who have an email address and a mobile phone number (or whose parent or legal guardian does)
- People who are able to understand the study information and the form used to agree to participation — if the person is a child, their parent or legal guardian must also be able to do this
- People who are able to read and complete questionnaires written in French — if the person is a child, their parent or legal guardian must also be able to do this
- People who are covered by the local social security system in France
Who may not be able to join:
- People who are currently pregnant
- People who have a known allergy to any of the materials used in the Omnipod 5 System, including the patch, the small tube (cannula), or the glucose sensor
- People who are not able to continue being seen at the same clinic for the full length of the study, or who are unwilling or unable to stay in contact with their healthcare team
- People who are already taking part in another clinical trial or study that does not allow them to join additional studies
- Adults who are under a formal legal protection arrangement such as guardianship, curatorship, or tutorship (confirm with trial site)
- Adults who are otherwise legally restricted in their freedom (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jean-Pierre Riveline, MD, PhD, Centre Universitaire du Diabète et ses complications Hôpital Lariboisière
Phone: 978-600-7000
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in the percentage of time in the 70 - 180 mg/dL range
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.